Stock Watch: Getting Real About Antibody-Drug Conjugates’ Potential
AstraZeneca’s Enhertu Re-Energized The Space But There Are Limits
Executive Summary
Antibody-drug conjugates have come a long way in two decades but pricing, defined target expression levels, toxicity and possibly the competition may defuse recent fireworks.